Additionally, VLCKD reduced the number of patients with severe liver steatosis and increased lysosomal acid lipase (LAL), which is involved in the pathogenesis of NAFLD. This evidence concerns the gene LIPA and metabolic dysfunction-associated steatotic liver disease.